Hybrids, consisting of two or more constituents (primarily inorganic and organic phases) at the nanometer or molecular level, have recently emerged as biomaterials for drug delivery applications. Hybrids usually show characteristics in between the original phases or even exhibit unique physical, chemical, and biological properties. Hybrid systems combine the benefits of different structural components to synergize the outcome of drug delivery for therapeutic applications. Many attempts have been dedicated to design and synthesize novel hybrid biomaterials with several concurrent features, such as favorable size/shape for efficient drug loading and controlled drug release, desired surface properties for targeting specific organs/tissues/cells, and satisfactory biocompatibility and biodegradation rate for clinical translation.
The aim of the current Research Topic is to report promising, recent, and novel research in the field of hybrids for drug delivery. Hybrids are attracting increasing attention as new biomaterials and also as promising building blocks of advanced medical devices for smart drug delivery strategies. However, many challenges still exist, for example:
- Rational design of inorganic/organic phases toward efficient drug loading, controlled drug release and theranostics
- Controlling the biodistribution of hybrid nanomaterials for precision drug delivery and minimized off-target effects
- Releasing drug in response to the pathological features of diseases for enhanced therapeutic efficacy and reduced side effects
Types of manuscripts to be featured mainly include Original Research and Perspective articles. Review articles that describe the current state-of-the-art in hybrids for drug delivery are also welcomed.
Topics to be investigated in this collection may include (but are not limited to):
• Synthesis of hybrids for drug delivery applications
• Development of carriers and medical devices based on hybrids for drug delivery
• Hybrids for efficient drug loading and controlled drug release
• Hybrids for theranostics
• Hybrid nanoparticles/fibers/scaffolds for smart/controlled drug delivery
• Hybrids for the delivery of drugs for anti-cancer/anti-inflammatory as well as other diseases therapy
• Cellular response and protein interaction of hybrids
• In vivo behavior of hybrids
Hybrids, consisting of two or more constituents (primarily inorganic and organic phases) at the nanometer or molecular level, have recently emerged as biomaterials for drug delivery applications. Hybrids usually show characteristics in between the original phases or even exhibit unique physical, chemical, and biological properties. Hybrid systems combine the benefits of different structural components to synergize the outcome of drug delivery for therapeutic applications. Many attempts have been dedicated to design and synthesize novel hybrid biomaterials with several concurrent features, such as favorable size/shape for efficient drug loading and controlled drug release, desired surface properties for targeting specific organs/tissues/cells, and satisfactory biocompatibility and biodegradation rate for clinical translation.
The aim of the current Research Topic is to report promising, recent, and novel research in the field of hybrids for drug delivery. Hybrids are attracting increasing attention as new biomaterials and also as promising building blocks of advanced medical devices for smart drug delivery strategies. However, many challenges still exist, for example:
- Rational design of inorganic/organic phases toward efficient drug loading, controlled drug release and theranostics
- Controlling the biodistribution of hybrid nanomaterials for precision drug delivery and minimized off-target effects
- Releasing drug in response to the pathological features of diseases for enhanced therapeutic efficacy and reduced side effects
Types of manuscripts to be featured mainly include Original Research and Perspective articles. Review articles that describe the current state-of-the-art in hybrids for drug delivery are also welcomed.
Topics to be investigated in this collection may include (but are not limited to):
• Synthesis of hybrids for drug delivery applications
• Development of carriers and medical devices based on hybrids for drug delivery
• Hybrids for efficient drug loading and controlled drug release
• Hybrids for theranostics
• Hybrid nanoparticles/fibers/scaffolds for smart/controlled drug delivery
• Hybrids for the delivery of drugs for anti-cancer/anti-inflammatory as well as other diseases therapy
• Cellular response and protein interaction of hybrids
• In vivo behavior of hybrids